Picture of Biondvax Pharmaceuticals logo

BVXV Biondvax Pharmaceuticals Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Annual cashflow statement for Biondvax Pharmaceuticals, fiscal year end - December 31st, ILS millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-34.6-87.7-109-4.46-40
Depreciation
Non-Cash Items21.712.333.8-55.923.9
Other Non-Cash Items
Changes in Working Capital2.3417.9-3.35-14.6-10.9
Change in Accounts Receivable
Change in Accounts Payable
Change in Payable / Accrued Expenses
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities-10.1-57.2-77.1-72.5-24.5
Capital Expenditures-4.51-23.7-7.43-6.13-0.43
Purchase of Fixed Assets
Other Investing Cash Flow Items11.30.2770.230.1970.069
Sale of Fixed Assets
Change in Net Investments
Other Investing Cash Flow
Cash from Investing Activities6.76-23.5-7.2-5.93-0.361
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities61.884.385.213.767.8
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash55.74.5-3.42-6344.6

Or unlock with your email

Or unlock with your email